TY - JOUR
T1 - Oncologic outcomes in resected ampullary cancer
T2 - Relevance of histologic subtype and adjuvant chemotherapy
AU - Affi Koprowski, Marina
AU - Sutton, Thomas L.
AU - Brinkerhoff, Brian T.
AU - Grossberg, Aaron
AU - Sheppard, Brett C.
AU - Mayo, Skye C.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/6
Y1 - 2021/6
N2 - Background: Outcomes in ampullary cancer (AC) may differ by pathologic subtype. No guidelines exist for the administration of adjuvant therapy (AT). We sought to evaluate the effect of subtype and AT on survival. Methods: An institutional review of patients undergoing resection for AC from 2008-17 was performed. Recurrence-free (RFS) and overall survival (OS) were assessed by Kaplan-Meier and Cox proportional hazards modeling. Results: Of 53 patients, two-thirds (62%) were stage III. Histologic subtype was evenly split between intestinal and pancreatobiliary (43% and 40%). Half of patients received AT. RFS and OS were 25 (95% CI 16–32) and 41 (CI 22–60) months, respectively, without significant difference by subtype. Stage II/III disease was associated with worse OS (HR 3.7, P = 0.03), which was improved with receipt of AT (HR 0.44, P < 0.05). Conclusion: Stage is the primary determinant of survival in AC, which may be improved with AT.
AB - Background: Outcomes in ampullary cancer (AC) may differ by pathologic subtype. No guidelines exist for the administration of adjuvant therapy (AT). We sought to evaluate the effect of subtype and AT on survival. Methods: An institutional review of patients undergoing resection for AC from 2008-17 was performed. Recurrence-free (RFS) and overall survival (OS) were assessed by Kaplan-Meier and Cox proportional hazards modeling. Results: Of 53 patients, two-thirds (62%) were stage III. Histologic subtype was evenly split between intestinal and pancreatobiliary (43% and 40%). Half of patients received AT. RFS and OS were 25 (95% CI 16–32) and 41 (CI 22–60) months, respectively, without significant difference by subtype. Stage II/III disease was associated with worse OS (HR 3.7, P = 0.03), which was improved with receipt of AT (HR 0.44, P < 0.05). Conclusion: Stage is the primary determinant of survival in AC, which may be improved with AT.
KW - Adjuvant therapy
KW - Ampullary cancer
KW - Cancer outcomes
KW - Hepatopancreatobiliary surgery
KW - Pancreatoduodenectomy
UR - http://www.scopus.com/inward/record.url?scp=85103977219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103977219&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2021.04.001
DO - 10.1016/j.amjsurg.2021.04.001
M3 - Article
C2 - 33883071
AN - SCOPUS:85103977219
SN - 0002-9610
VL - 221
SP - 1128
EP - 1134
JO - American journal of surgery
JF - American journal of surgery
IS - 6
ER -